Total Company Value: XTL Bio (XTLB)

XTL Bio - graphic logo of issuer XTLB

XTL Biopharmaceuticals focuses on developing treatments for blood cancer. The market price visualization on GURU.Markets, where the indicator stands at 5.19, illustrates the potential of the hMTS drug within the rare oncological pathology niche. The business relies on acquiring rights to new medications and forming alliances to combat lupus. High unmet demand for systemic autoimmune disorder therapies guarantees stable sales following successful tests.

XTLB (xtlbio.com) Total Company Value history from 11/23/2025 to 03/31/2026

XTL Biopharmaceuticals (XTLB) - metric breakdowns and financial figures

- price and consensus price forecast:
Price XTL Biopharmaceuticals Ltd|XTLB - Price Target Chart
- market capitalization data:
Market Value XTL Biopharmaceuticals|XTLB - Enterprise Value
- book capitalization data:
Net Assets per Single Share XTL Biopharmaceuticals|XTLB - Company Book Value|Market Capitalization to Net Assets xtlbio.com|XTLB - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio XTL Biopharmaceuticals|XTLB - Long-Term Debt to Capital|Short-Term Debt to Capital xtlbio.com|XTLB - Company Debts|Debt to Net Assets Ratio XTL Biopharmaceuticals|XTLB - Company Long-Term Debt|Company Current Liabilities XTL Biopharmaceuticals
Comprehensive company analysis:XTL Biopharmaceuticals Ltd (XTLB)
Original product of XTL Biopharmaceuticals

XTL Biopharmaceuticals focuses on developing innovative antibodies for the treatment of systemic lupus erythematosus. The enterprise value (EV) reflects the total cost of acquiring the business, summing market capitalization and net debt. This metric allows for an assessment of the company's actual scale beyond the share price. Investors utilize it to analyze the efficiency of capital expenditures on research and development. The EV history clearly demonstrates the trend of the market valuation regarding the potential for future drug commercialization.

Competitor analysis for XTL Biopharmaceuticals

argenx N.V. - Aggregate Business Value|BNTX - Total Company Value|ABVX - Total Company Value|ADMA Biologics (ADMA) - Enterprise Value|PTGX (protagonist-inc.com) - Total Company Value|Total Company Value Immunovant IMVT|Full Business Value Kiniksa Pharmaceuticals, Ltd.|Grifols Group (GRFS) - Enterprise Value|Value Adjusted for Debt and Cash Adaptive Biotechnologies Inc. (ADPT)|Enterprise Value CLDX (Celldex Therapeutics)|auriniapharma.com - Enterprise Value|Total Company Value BioCryst Pharmaceuticals (BCRX)|VERA: Value Adjusted for Debt and Cash|DNTH (Dianthus Pharma) - Total Company Value|Pharvaris Pharma (PHVS) - Real Price to Acquire Entire Company|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com (TRML)|Precigen (PGEN) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Pharming Group NV (PHAR)|Enterprise Value NKTR|Upstream Pharma - Company Buyout Price|ZBIO: Total Company Value|IMNM: Real Price to Acquire Entire Company|GOSS (Gossamer Bio) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|SEPN (Septerna Corp) - Real Price to Acquire Entire Company|Enterprise Value PVLA|Total Company Value Savara Inc. SVRA|Business Value rigel.com (RIGL)|ANAB: Enterprise Value|ATXS - Total Enterprise Value|enGene Bio (ENGN) - Real Price to Acquire Entire Company|RAPT Therapeutics Inc. (RAPT) - Business Value|JBIO - Real Price to Acquire Entire Company|ACRS (aclaristx.com) - Aggregate Business Value|Total Company Value Kyverna Therapeutics, Inc.|Total Company Value Tiziana Life Sciences Ltd. (TLSA)|Cabaletta Bio, Inc (CABA) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Ventyx Biosciences, Inc (VTYX)|Enterprise Value Theratechnologies Inc. THTX|Total Company Value avalotx.com AVTX|Enterprise Value ELDN (Eledon Pharmaceuticals, Inc.)|AGEN: Company Buyout Price|Total Company Value CLYM|ZURA (Zura Bio Ltd) - Total Enterprise Value|Total Company Value aTyr Pharma, Inc. ATYR|Full Business Value Adagene Corp|ImageneBio Inc (IMA) - Enterprise Value|Value Adjusted for Debt and Cash shattucklabs.com (STTK)|Enterprise Value EQ (Equillium)|Connect Biopharma Holdings - Enterprise Value|Total Company Value Immunic Inc (IMUX)|ATRA: Value Adjusted for Debt and Cash|IFRX (inflarx.de) - Total Company Value|X4 Pharmaceuticals Inc. (XFOR) - Real Price to Acquire Entire Company|ACET (Adicet Bio Inc.) - Enterprise Value|Enterprise Value Celularity Corp|Enterprise Value INMB (INmune Bio, Inc.)|Real Price to Acquire Entire Company barinthusbio.com (BRNS)|KZR: Enterprise Value|SABS - Total Enterprise Value|Akari Therapeutics plc - Real Price to Acquire Entire Company|Enlivex Therapeutics (ENLV) - Enterprise Value|QTTB - Real Price to Acquire Entire Company|geovax.com (GOVX) - Aggregate Business Value|EDSA: Enterprise Value|Company Buyout Price iBio Inc|Enterprise Value CARM (Carisma Therapeutics)|Real Price to Acquire Entire Company boltbio.com (BOLT)|Enterprise Value HCWB (HCW Biologics)|Aptevo Therapeutics, Inc. - Enterprise Value|AIM - Total Company Value|ADTX: Total Company Value|GRI Bio Corp - Total Company Value|Company Buyout Price XORTX Corp|Real Price to Acquire Entire Company Vyome Holdings Inc (HIND)|Business Value revbiosciences.com (REVB)|Real Price to Acquire Entire Company Indaptus Therapeutics, Inc.|Aggregate Business Value SCNI (Scinai Immunotherapeutics Ltd)|Total Company Value CalciMedica CALI|Total Company Value Affimed NV AFMD|ALLK - Enterprise Value|HOOK: Total Company Value|Total Company Value igmbio.com (IGMS)|iTeos Therapeutics Inc (ITOS) - Full Business Value|OCEA - Enterprise Value|Value Adjusted for Debt and Cash TC BioPharm Ltd|Enterprise Value THRD